Digoxin is a digitalis glycoside used to treat atrial fibrillation and heart failure. Its effects include increasing the force of heart contractions and slowing ventricular response in atrial fibrillation. Therapeutic drug monitoring is important due to its narrow therapeutic index and interactions with other drugs and conditions affecting absorption, distribution, and elimination. The optimal therapeutic range is 0.8-2 ng/mL, with risks of toxicity above 2.5 ng/mL. Factors like renal impairment, liver disease, hypothyroidism, and hypokalemia can impact digoxin levels and require dosage adjustments.
This presentation gives complete in-depth information about therapeutic drug monitoring of DIGOXIN. Points covered are:
1. Basic pharmacokinetics
2. Target concentration levels
3. Dosage forms available and their bioavailability
4. Procedure to conduct TDM
5. The principle of DIGOXIN estimation
6. Interpretation of TDM results.
7. TDM algorithm
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders- Phenytoin, Valproic acid, Carbamazepine are major drugs used in epilepsy disorders. These drug need TDM to ensure their proper usage.
This presentation gives complete in-depth information about therapeutic drug monitoring of DIGOXIN. Points covered are:
1. Basic pharmacokinetics
2. Target concentration levels
3. Dosage forms available and their bioavailability
4. Procedure to conduct TDM
5. The principle of DIGOXIN estimation
6. Interpretation of TDM results.
7. TDM algorithm
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders- Phenytoin, Valproic acid, Carbamazepine are major drugs used in epilepsy disorders. These drug need TDM to ensure their proper usage.
Introduction to dosage regimen and Individualization of dosage regimenKLE College of pharmacy
Introduction of Dosage regimen, Approaches for design of dosage regimen, Individualization, Advantages, Dosage in neonates, Geriatrics, Renal and Hepatic impaired Patients.
Clinical pharmacokinetics and its application--
1)definition
2) APPLICATIONS OF CLINICAL PHARMACOKINETICS
Design of dosage regimens:
a) Nomograms and Tabulations in designing dosage regimen,
b) Conversion from intravenous to oral dosing,
c) Determination of dose and dosing intervals,
d) Drug dosing in the elderly and pediatrics and obese patients.
Pharmacokinetics of Drug Interaction:
a) Pharmacokinetic drug interactions
b) Inhibition and Induction of Drug metabolism
c) Inhibition of Biliary Excretion.
Therapeutic Drug monitoring:
a) Introduction
b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs).
c) Indications for TDM. Protocol for TDM.
d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy.
e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations
Dosage adjustment in Renal and Hepatic Disease.
a. Renal impairment
b. Pharmacokinetic considerations
c. General approach for dosage adjustment in renal disease.
d. Measurement of Glomerular Filtration rate and creatinine clearance.
e. Dosage adjustment for uremic patients.
f. Extracorporeal removal of drugs.
g. Effect of Hepatic disease on pharmacokinetics.
Population Pharmacokinetics.
a) Introduction to Bayesian Theory.
b) Adaptive method or Dosing with feedback.
c) Analysis of Population pharmacokinetic Data
Introduction to dosage regimen and Individualization of dosage regimenKLE College of pharmacy
Introduction of Dosage regimen, Approaches for design of dosage regimen, Individualization, Advantages, Dosage in neonates, Geriatrics, Renal and Hepatic impaired Patients.
Clinical pharmacokinetics and its application--
1)definition
2) APPLICATIONS OF CLINICAL PHARMACOKINETICS
Design of dosage regimens:
a) Nomograms and Tabulations in designing dosage regimen,
b) Conversion from intravenous to oral dosing,
c) Determination of dose and dosing intervals,
d) Drug dosing in the elderly and pediatrics and obese patients.
Pharmacokinetics of Drug Interaction:
a) Pharmacokinetic drug interactions
b) Inhibition and Induction of Drug metabolism
c) Inhibition of Biliary Excretion.
Therapeutic Drug monitoring:
a) Introduction
b) Individualization of drug dosage regimen (Variability – Genetic, Age and Weight, disease, Interacting drugs).
c) Indications for TDM. Protocol for TDM.
d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy.
e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations
Dosage adjustment in Renal and Hepatic Disease.
a. Renal impairment
b. Pharmacokinetic considerations
c. General approach for dosage adjustment in renal disease.
d. Measurement of Glomerular Filtration rate and creatinine clearance.
e. Dosage adjustment for uremic patients.
f. Extracorporeal removal of drugs.
g. Effect of Hepatic disease on pharmacokinetics.
Population Pharmacokinetics.
a) Introduction to Bayesian Theory.
b) Adaptive method or Dosing with feedback.
c) Analysis of Population pharmacokinetic Data
Digoxin & Nitroglycerin by Dr. Sanaullah AslamSanaullah Aslam
Your Feedback will be highly appreciated. This presentation was made for students at pharmacy institute in a project of clinical pharmacy and use of digoxin and nitroglycerin. This presentation is made so that you can present it in a same session, without any change.
Pharmacokinetic concepts and principles in humans in order to design individualized dosage regimens which optimize the therapeutic response of a medication while minimizing the chance of an adverse drug reaction.
Residual Inflammatory Risk inPatients With Low LDL CholesterolLevels Underg...Shadab Ahmad
Patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) are at high risk of future adverse ischemic events.
Indeed, increased inflammatory status pre- and post-PCI has also been associated with poor prognosis, and control of the residual inflammatory risk (RIR) in the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial has recently opened new perspectives in the field of secondary prevention.
Diabetic nephropathy is a clinical syndrome characterized by the following :
Persistent albuminuria (>300 mg/d or >200 μg/min) that is confirmed on at least 2 occasions 3-6 months apart.
Progressive decline in the glomerular filtration rate (GFR).
Elevated arterial blood pressure.
Three major histologic changes occur in the glomeruli of persons with diabetic nephropathy:
First, mesangial expansion is directly induced by hyperglycemia, perhaps via increased matrix production or glycation of matrix proteins.
Second, thickening of the glomerular basement membrane (GBM) occurs.
Third, glomerular sclerosis caused by intraglomerular hypertension (induced by dilatation of the afferent renal artery or from ischemic injury induced by hyaline narrowing of the vessels supplying the glomeruli).
These different histologic patterns appear to have similar prognostic significance.
Several issues are key in the medical care of patients with diabetic nephropathy.
These include glycemic control, management of hypertension, and reducing dietary salt intake and phosphorus and potassium restriction in advanced cases.
A meta-analysis from the Cochrane Database shows a large fall in blood pressure with salt restriction, similar to that of single-drug therapy
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
We all have good and bad thoughts from time to time and situation to situation. We are bombarded daily with spiraling thoughts(both negative and positive) creating all-consuming feel , making us difficult to manage with associated suffering. Good thoughts are like our Mob Signal (Positive thought) amidst noise(negative thought) in the atmosphere. Negative thoughts like noise outweigh positive thoughts. These thoughts often create unwanted confusion, trouble, stress and frustration in our mind as well as chaos in our physical world. Negative thoughts are also known as “distorted thinking”.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
The Art Pastor's Guide to Sabbath | Steve ThomasonSteve Thomason
What is the purpose of the Sabbath Law in the Torah. It is interesting to compare how the context of the law shifts from Exodus to Deuteronomy. Who gets to rest, and why?
2. Action and uses
• Digoxin is the most widely used of the digitalis glycosides.
• Its primary actions on the heart are those of increasing the force of
contraction and decreasing conduction through the atrioventricular
node.
• Currently, its main role is in the treatment of atrial fibrillation by
slowing down the ventricular response, although it is also used in the
treatment of heart failure in the presence of sinus rhythm.
• The primary method of monitoring its clinical effect in atrial
fibrillation is by measurement of heart rate but knowledge of its phar-macokinetics
can be helpful in predicting a patient's dosage
requirements.
3. Plasma concentration–responserelationship
• <0.5 μcg/L: no clinical effect
• 0.7 μcg/L: some positive inotropic and conduction blocking
effects
• 0.8–2 μcg/L: optimum therapeutic range (0.5–0.9 μcg/L in
patients >65)
• 2–2.5 μcg/L: increased risk of toxicity, although tolerated in
some patients
• >2.5 μcg/L: gastro-intestinal, cardiovascular system and central
nervous system toxicity.
4. absorption
•Digoxin is poorly absorbed from the gastro-intestinal
tract, and dissolution time affects the
overall bioavailability. The two oral formulations
of digoxin have different bioavailabilities:
• F (tablets) =0.65
•F (liquid) =0.8
5. Distribution
• Digoxin is widely distributed and extensively bound in
varying degrees to tissues throughout the body. This results
in a high apparent volume of distribution. Digoxin volume of
distribution can be estimated using the equation 7.3 L/kg
(ideal body weight (BWt)) which is derived from population
data. However, distribution is altered in patients with renal
impairment, and a more accurate estimate in these patients
is given by:
Vd= 3.8 × ideal BWt (3.1 creatinine clearance (mL/min))
6. •A two-compartment model best describes
digoxin disposition, with a distribution time of 6–
8 h. Clinical effects are seen earlier after
intravenous doses, since the myocardium has a
high blood perfusion and affinity for digoxin.
Sampling for TDM must be done no sooner than
6 h post- dose, otherwise an erroneous result
will be obtained.
7. elimination
•Digoxin is eliminated primarily by renal excretion
of unchanged drug (60–80%), but some hepatic
metabolism occurs (20–40%). The population
average value for digoxin clearance is:
digoxin clearance (mL/min) = 0.8 × BWt +
(creatinine clearance (mL/min))
8. •However, patients with severe congestive heart
failure have a reduced hepatic metabolism and a
slight reduction in renal excretion of digoxin:
digoxin clearance (mL/min) = 0.33× BWt
+(0.9 × creatinine clearance (mL/min))
• Ideal body weight should be used in these
equations
9. Practical implications
• Using population averages it is possible to predict plasma
concentrations from specific dosages, particularly since the time to
reach the steady state is long.
• Population values are only averages, and individual values may vary.
In addition, a number of diseases and drugs affect digoxin disposition.
• As can be seen from the preceding discussion, congestive heart
failure, hepatic and renal diseases all decrease the elimination of
digoxin.
• In addition, hypothyroidism increases the plasma concentration
(decreased metabolism and renal excretion) and increases the
sensitivity of the heart to digoxin.
10. Practical implications
• Hyperthyroidism has the opposite effect.
• Hypokalemia, hypercalcaemia, hypomagnesaemia and hypoxia all
increase the sensitivity of the heart to digoxin.
• There are numerous drug interactions reported of varying clinical
significance. The usual cause is either altered absorption or clearance.
11. CLINICAL MONITORING PARAMETERS
•Monitor symptoms of CHF including left sided
failure, pulmonary edema, right sided failure
•As excreted by kidney renal functions should be
monitored 2-3 times
•Serum concentration measurements is also
important in many cases